By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

Novel and promising designs of ADC - Bispecific ADCs (BsADCs) The main source of ADC toxicity is the non-specific binding of antibodies to antigens. 2 Improving the selectivity and specificity of ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen ... of ImmunoGen's payload technologies, the toxic molecules that add a cell-killing ...

To gain a better understanding of the data on ADC combinations in aUC ... a high chance of encountering things like hematological toxicity, neutropenia or anemia may require more frequent blood ...

Background: ImmunoGen’s Patent Application & Dispute - In 2014, ImmunoGen, Inc. (Immunogen) filed U.S. Patent Application ...

BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1 ... targeting dual epitopes of ROR1 with the small-molecule toxin eribulin. It is the world's first anti-ROR1 Bi-paratopic ...

Akeso is dedicated to transforming the global oncology treatment landscape by establishing new standards of care for cancer patients worldwide. A key element of this mission is the company's "IO 2.0 + ...

reducing the risk of off-target toxicity. As CDH17 is an abundantly expressed and rapidly internalizing transmembrane protein on GI cancer cells, CDH17 is ideally suited for an ADC-mediated drug ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.